Glenmark Pharmaceuticals today said its generic arm has completed royalty payment to Paul Capital Partners' Royalty Fund for developing dermatological products for the US market with the final tranche of USD 28.8 million (over Rs 140 crore).
With Indian pharma companies willing to cash out, is Glenn Saldanha India’s best bet for a home-grown drug?
Sushil Finance is bullish on Glenmark Pharmaceuticals and has recommended accumulate rating on the stock with a target of Rs 368 in its September 13, 2011 research report.
Glenmark Pharmaceuticals today said it has started Phase-IIb human trials of its 'Revamilast' molecule, which is being developed for treatment of inflammatory disorders like asthma and rheumatoid arthritis.
KRChoksey is bullish on Glenmark Pharmaceuticals and has recommended buy rating on the stock with a target of Rs 412 in its August 08, 2011 research report.
Indian drugmaker Glenmark Pharmaceuticals said on Monday it has filed for arbitration claims against its partner Napo Pharmaceuticals to prevent the latter from distributing an HIV-associated drug in Glenmark's territories through relief agencies.
PINC Research is bullish on Glenmark Pharmaceuticals and has recommended buy rating on the stock with a target of Rs 359 in its July 26, 2011 research report.
Glenmark Pharmaceuticals today said it has received USD 15 million (over Rs 65 crore) from Salix Pharmaceuticals Inc, USA, as an advance payment to upgrade its plant for production of Crofelemer, used for treating diarrhoea.
Glenmark Pharmaceuticals said on Tuesday it has received USD 15 million from US-based Salix Pharmaceuticals towards upgrading the manufacturing facility for HIV-associated diarrhea drug 'Crofelemer'.
Mid-sized Indian drugmakers are expected to post steady to strong revenue growth in April-June, riding healthy domestic and overseas demand, but higher would crimp margins.
Glenmark Pharmaceuticals today said it has received Rs 110 crore from Sanofi, as second tranche of oulicensing fee for a deal with French drug major, taking the total upfront receipts to about Rs 220 crore.
Glenmark Pharmaceuticals today said it has settled a patent infringement litigation with Daiichi Sankyo and Genzyme paving way for it to market generic Colesevelam Hydrochloride used for treating diabetes and high cholesterol in the US market.
Glenmark Pharmaceuticals on Monday said its US subsidiary Glenmark Generics Inc has received US health regulator's approval to market its generic oral contraceptives Norgestimate and Ethinyl Estradiol tablets in the American market.
Glenmark Generics USA has got final approval from US Food and Drugs Administration (FDA) for their abbreviated new drug application for Norgestimate and Ethinyl Estradiol tablets.
Glenmark Generics Inc, the US arm of Glenmark Generics has received final abbreviated new drug approval from the US Food and Drugs Administration for its version of Mupirocin ointment, which is an antibacterial used to treat skin infection called impetigo.
Glenmark Pharmaceuticals' USA unit has entered into a royalty-bearing license agreement with Triax Pharmaceuticals, Astellas Pharma Europe BV and Astellas Pharma International BV to settle last year's patent infringement suit against the comercialisation of generic version of Locoid Lipocream, the company said in a press release Wednesday.
Deven Choksey, MD, KR Choksey Shares and Securities Private Ltd in an interview on CNBC-TV18 spoke about his reading of the market. He also gave his views on specific stocks and sectors and how he sees them playing out going forward. He spoke about Glenmark Pharmaceuticals, Oil Marketing Companies (OMCs) and L&T.
Glenn Saldanha, managing director and CEO of Glenmark Pharmaceuticals, in an interview with CNBC-TV18's Udayan Mukherjee and Mitali Mukherjee, said that its business in India is growing at 23-24%, while its business in US is expected to grow 25% in FY12.
Glenmark Pharmaceuticals said its arm Glenmark Generics has settled a patent infringement dispute with US-based Nycomed over a generic version of Fluticasone Propionate skin lotion.
Glenmark Generics Inc, the US arm of India’s Glenmark Pharmaceuticals has received final approval from US Foods and Drugs Administration, for its Abbreviated New Drug Application (ANDA) for Fluticasone Propionate skin lotion.
Indian mid-sized drugmakers are expected to report sluggish sales growth in January-March as delayed product approvals and rising operational expenses take a toll on profit margins.
Glenmark Pharmaceuticals on Thursday announced the discovery of a new molecule for oncology treatment and said it would file an application for phase-I trials in the fourth quarter of FY12.
In an interview with CNBC-TV18, Glenn Saldanha, managing director and chief executive officer of Glenmark Pharmaceuticals said,"Tarka is not a major contributor any more to the topline for the US business."
Drug maker Glenmark Pharmaceuticals' sales in the US is back on track and the company is hopeful of clocking a sequential growth in quarterly topline for the next 5-6 months. Glen Saldhana, chief executive officer of the company said in an exclusive interview to CNBC-TV18 that the company has a host of new products lined up in the coming quarters.
The BSE Sensex is expected to start higher on Friday, supported by firmer Asian peers, and will be on course to register their second weekly gain in three.